ACAD - ACADIA PHARMACEUTICALS INC

22.5
-0.310   -1.378%

Share volume: 1,953,461
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$22.81
-0.31
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 45%
Dept financing 25%
Liquidity 75%
Performance 44%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.39%
1 Month
-7.14%
3 Months
-15.25%
6 Months
-11.76%
1 Year
23.22%
2 Year
-5.26%
Key data
Stock price
$22.50
P/E Ratio 
11.56
DAY RANGE
$22.28 - $22.96
EPS 
$2.32
52 WEEK RANGE
$13.40 - $28.35
52 WEEK CHANGE
$24.45
MARKET CAP 
4.519 B
YIELD 
N/A
SHARES OUTSTANDING 
170.495 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.34
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,421,425
AVERAGE 30 VOLUME 
$1,820,918
Company detail
CEO: Stephen R. Davis
Region: US
Website: acadia-pharm.com
Employees: 510
IPO year: 2004
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

ACADIA Pharmaceuticals Inc. focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Recent news